Arginine, arginine analogs and nitric oxide production in chronic kidney disease

Nature Clinical Practice Nephrology

Volumn 2, Issue 4, 2006, Pages 209-220

  Baylis, Chris ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Arginase; Asymmetric dimethylarginine; Cardiovascular events; Dimethylarginine dimethylaminohydrolase; L arginine transporters

Indexed keywords

ARGININE; ARGININE DERIVATIVE; DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

AMINO ACID TRANSPORT; BIOSYNTHESIS; CATABOLISM; CHRONIC KIDNEY DISEASE; DNA POLYMORPHISM; ENDOTHELIUM CELL; HUMAN; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUPPLEMENTATION; URINARY EXCRETION;

ABSORPTION; AMIDOHYDROLASES; ARGININE; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; ENZYME INHIBITORS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYMORPHISM, GENETIC;

EID: 33646886617     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0143     Document Type: Review

References (113)

1. Baylis C and Vallance P (1998) Measurement of nitrite and nitrate (NOx) levels in plasma and urine; what does this measure tell us about the activity of the endogenous nitric oxide. Current Opinion Nephrol Hypertens 7: 1-4
2. Schmidt R et al. (1999) Indices of activity of the nitric oxide system in patients on hemodialysis. Am J Kidney Dis 34: 228-234
3. Schmidt RJ et al. (1999) Nitric oxide production is low in end stage renal disease patients on peritoneal dialysis. Am J Physiol 276: F794-F797
4. Schmidt RJ and Baylis C (2000) Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58: 1261-1266
5. Blum M et al. (1998) Low nitric oxide production in patients with chronic renal failure. Nephron 79: 265-268
6. Wever R et al. (1999) Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 19: 1168-1172
7. Lau T et al. (2000) Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest 105: 1217-1225
8. Vaziri ND et al. (1998) Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 274: F642-F649
9. Wagner L et al. (2002) Reduced NOS activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 62: 532-536
10. Erdely A et al. (2003) Protection of Wistar Furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 14: 2526-2533
11. Szabo A et al. (2003) Renal neuronal nitric oxide synthase protein expression as a marker of renal function. Kidney Int 64: 1765-1771
12. Erdely A et al. (2004) Protection against puromycin aminonucleoside- induced chronic renal disease in the Wistar-Furth rat. Am J Physiol 287: F81-F89
13. Erdely A et al. (2003) Sexual dimorphism in the aging kidney: effects on injury and nitric oxide system. Kidney Int 63: 1021-1026
14. Thambyrajah J et al. (2000) Abnormalities of endothelial function in patients with predialysis renal failure. Heart 83: 205-209
15. Böger RH and Zoccali C (2003) ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis (Suppl 4): S23-S28
16. Foley RN et al. (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (Suppl 3): S112-S119
17. Baigent C et al. (2000) Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152
18. Landray MJ et al. (2004) Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 43: 244-253
19. Himmelfarb J (2004) Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin Dial 17: 449-454
20. Zatz R and Baylis C (1998) Chronic nitric oxide inhibition model six years on. Hypertension 32: 958-964
21. Peppa M et al. (2004) Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 43: 690-695
22. Wu G and Morris SM (1998) Arginine metabolism: nitric oxide and beyond. Biochem J 33: 1-17
23. Brosnan ME and Brosnan JT (2004) Renal arginine metabolism. J Nutr 134 (Suppl 10): S2791-S2795
24. Tizianello A et al. (1980) Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 65: 1162-1173
25. Reyes AA et al. (1994) Role of arginine in health and in renal disease. Am J Physiol 267: F331-F346
26. Xiao S et al. (2001) Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol 280: F989-F995
27. Wagner L et al. (2002) Urea transporters are widely distributed in endothelial cells and mediate inhibition of L-arginine transport. Am J Physiol Renal Physiol 283: F578-F582
28. Devés R and Boyd CAR (1998) Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 78: 487-545
29. Swendseid ME et al. (1975) Amino acid metabolism in the chronically uremic rat. Clin Nephrol 3: 240-246
30. Bergström J et al. (1990) Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int 38: 108-114
31. Vallance P et al. (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575
32. Fleck C et al. (2001) Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 78: S14-S18
33. Kielstein JT et al. (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10: 594-600
34. Wahbi N et al. (2001) Dimethylarginines in chronic renal failure. J Clin Pathol 54: 470-473
35. Bogle RG et al. (1995) Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol Cell Physiol 269: C750-C756
36. + carrier HCAT-2B. Nitric Oxide 1: 65-73
37. Schwartz IF et al. (2006) Arginine uptake is attenuated, through modulation of cationic amino acid transporter-1, in uremic rats. Kidney Int 69: 298-303
38. +L as the high-affinity transporter for L-arginine in human platelets: up-regulation of L-arginine influx in uraemia. Eur J Physiol 438: 573-575
39. Mendes Ribeiro AC et al. (1997) Transport of L-arginine and the nitric oxide inhibitor NG-monomethyl-L-arginine in human erythrocytes in chronic renal failure. Clin Sci 93: 57-64
40. Cross JM et al. (2001) Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int 60: 2318-2323
41. Bennett-Richards KJ et al. (2002) Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 62: 1372-1378
42. Hand MF et al. (1998) Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 53: 1068-1077
43. De Nicola L et al. (1999) Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. Kidney Int 56: 674-684
44. Zhang XZ et al. (2001) L-arginine supplementation in young renal allograft recipients with chronic transplant dysfunction. Clin Nephrol 55: 453-459
45. Peters H et al. (1999) From rats to man: a perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 14: 1640-1650
46. McDonald KK et al. (1997) A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem 272: 31213-31216
47. Kurtz S and Harrison DG (1997) Insulin and the arginine paradox. J Clin Invest 99: 369-370
48. Palmer RMJ et al. (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666
49. Li C et al. (2005) Interaction of the eNOS with the CAT-1 arginine transporter enhances NO release by a mechanism not involving arginine transport. Biochem J 386: 567-574
50. Segal MS et al. (2006) Endothelial health and diversity in the kidney. J Am Soc Nephrol 7: 323-324
51. Zani BG and Bohlen HG (2005) Transport of extracellular L-arginine via cationic amino acid transporter is required during in vivo endothelial NO production. Am J Physiol Heart Circ Physiol 289: H1381-H1390
52. Ishizuka S et al. (2000) Agmatine inhibits cell proliferation and improves renal function in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 11: 2256-2264
53. Schwartz D et al. (1997) Agmatine affects glomerular filtration via a nitric oxide synthase-dependent mechanism. Am J Physiol 272: F597-F601
54. Morrissey JJ and Klahr S (1997) Agmatine activation of nitric oxide synthase in endothelial cells. Proc Assoc Am Physicians 109: 51-57
55. Li H et al. (2001) Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280: E75-E82
56. Sabbatini M et al. (2003) Arginase inhibition slows the progression of renal failure in rats and renal ablation. Am J Physiol Renal Physiol 284: F680-F687
57. Zhang C et al. (2004) Upregulation of vascular arginase in hypertension decreases nitric oxide mediated dilation of coronary arterioles. Hypertension 44: 935-943
58. Johnson FK et al. (2005) Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 288: 1057-1062
59. Demougeot C et al. (2005) Arginase inhibition reduces endothelial dysfunction and blood pressure rising in SHR. J Hypertension 23: 971-978
60. Xiao S et al. (2000) Plasma from ESRD patients inhibits nitric oxide synthase (NOS) activity in cultured human and bovine endothelial cells. Acta Phys Scand 168: 175-179
61. McAllister RJ et al. (1994) Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 45: 737-742
62. Leiper J and Vallance P (1999) Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43: 542-548
63. Achan V et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459
64. Kielstein JT et al. (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetric dimethylarginine in humans. Circulation 109: 172-177
65. Vallance P and Leiper J (2005) ADMA and kidney disease - marker or mediator. J Am Soc Nephrol 16: 2254-2256
66. Scalera F et al. (2005) Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16: 892-898
67. Ueno S et al. (1992) Distribution of free methylarginines in rat tissues and in the bovine brain. J Neurochem 59: 2012-2016
68. Casellas P and Jeanteur P (1978) Protein methylation in animal cells. I. Purification and properties of S-adenosyl-L-methionine: protein (arginine) N-methyltransferase from Krebs II ascites cells. Biochim Biophys Acta 519: 243-254
69. Casellas P and Jeanteur P (1978) Protein methylation in animal cells. II. Inhibition of S-adenosyl-L-methionine: protein (arginine) N-methyltransferase by analogs of S-adenosyl-L-homocysteine. Biochim Biophys Acta 519: 255-268
70. Liu Q and Dreyfuss G (1995) In vivo and in vitro arginine methylation of RNA-binding proteins. Mol Cell Biol 15: 2800-2808
71. Böger RH et al. (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87: 99-105
72. Osanai T et al. (2003) Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 42: 985-990
73. Leiper JM et al. (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343: 209-214
74. Tojo A et al. (1997) Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52: 1593-1601
75. Kimoto M et al. (1993) Detection of NG,NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys 300: 657-662
76. Nijveldt RJ et al. (2003) Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant 18: 2542-2550
77. Nijveldt RJ et al. (2002) Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 17: 1999-2002
78. MacAllister RJ et al. (1996) Regulation of nitric oxide synthesis by dimethlarginine dimethylaminohydrolase. British J Pharm 119: 1533-1540
79. Dayoub H et al. (2003) Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108: 3042-3047
80. Tran CT et al. (2000) Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 68: 101-105
81. Jones LC et al. (2003) Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 310: 836-843
82. Akbar F et al. (2005) Haplotypic association of DDAH1 with susceptibility to pre-eclampsia. Mol Hum Reprod 11: 73-77
83. Pettersson A et al. (1998) Increased circulating concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 77: 808-813
84. Ito A et al. (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99: 3092-3095
85. Leiper J et al. (2002) S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 99: 13527-13532
86. Millatt LJ et al. (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493-1498
87. Lin KY et al. (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106: 987-992
88. Stuhlinger MC et al. (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104: 2569-2575
89. Kimoto M et al. (1995) Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 135: 1175-1182
90. Saran R et al. (2003) Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 18: 2415-2420
91. Achan V et al. (2002) All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 90: 764-769
92. Deng S et al. (2004) Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Acta Pharmacol Sin 25: 1633-1639
93. DP Holden et al. (2003) Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 108: 1575-1580
94. Xiao S et al. (2001) Circulating eNOS inhibitory factor in some patients with chronic renal disease. Kidney Int 59: 1466-1472
95. Kielstein JT et al. (2002) Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-176
96. Zoccali C et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117
97. Zoccali C et al. (2002) Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13: 490-496
98. Zoccali C et al. (2002) Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62: 339-345
99. Surdacki A et al. (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33: 652-658
100. Valkonen VP et al. (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128
101. Sydow K et al. (2004) Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 9: 93-101
102. Bode-Böger SM et al. (2005) Asymmetric dimethylarginine (ADMA) accelerates cell senescence. Vasc Med 10 (Suppl 1): S65-S71
103. Guthrie SM et al. (2004) The NO pathway modulates hemangioblast activity of adult hematopoietic stem cells. Blood 105: 1916-1922
104. Thum T et al. (2005) Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 46: 1693-1701
105. Smith CL et al. (2003) Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 308: 984-989
106. Azuma H et al. (1995) Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 115: 1001-1004
107. De Groot K et al. (2004) Uremia causes endothelial progenitor cell deficiency. Kidney Int 66: 641-646
108. Ravani P et al. (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455
109. Fliser D et al. (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461
110. Anderstam B et al. (1997) Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 18: 1437-1442
111. Bergamini S et al. (2004) Relationship of asymmetric dimethylarginine to haemodialysis hypotension. Nitric Oxide 11: 273-278.
112. Kielstein JT et al. (2004) Low dialysance of asymmetric dimethylarginine (ADMA) - in vivo and in vitro evidence of significant protein binding. Clin Nephrol 62: 295-300
113. Baylis C (2005) Changes in renal hemodynamics and structure in the aging kidney; sexual dimorphism and the nitric oxide system. Exp Gerontol 40: 271-278